Related Experiment Video
Updated: May 11, 2026
A Reproducible Cartilage Impact Model to Generate Post-Traumatic Osteoarthritis in the Rabbit
Published on: November 21, 2023
Post-traumatic osteoarthritis: from mouse models to clinical trials
Christopher B Little1, David J Hunter
1Raymond Purves Bone and Joint Research Laboratories, Kolling Institute of Medical Research, Institute of Bone and Joint Research, University of Sydney at Royal North Shore Hospital, St Leonards, NSW 2065, Australia. christopher.little@ sydney.edu.au
Abstract:
Osteoarthritis (OA), the most common of all arthropathies, is a leading cause of disability and has a large (and growing) worldwide socioeconomic cost. Despite its burgeoning importance, translation of disease-modifying OA therapies from the laboratory into clinical practice has slowed. Differences between the OA models studied preclinically and the disease evaluated in human clinical trials contribute to this failure. Most animal models of OA induce disease through surgical or mechanical disruption of joint biomechanics in young individuals rather than the spontaneous development of age-associated disease. This instability-induced joint disease in animals best models the arthritis that develops in humans after an injurious event, known as post-traumatic OA (PTOA). Studies in genetically modified mice suggest that PTOA has a distinct molecular pathophysiology compared with that of spontaneous OA, which might explain the poor translation from preclinical to clinical OA therapeutic trials. This Review summarizes the latest data on potential molecular targets for PTOA prevention and modification derived from studies in genetically modified mice, and describes their validation in preclinical therapeutic trials. This article focuses on how these findings might best be translated to humans, and identifies the potential challenges to successful implementation of clinical trials of disease-modifying drugs for PTOA.
Insights
Post-traumatic osteoarthritis (PTOA) models in mice show distinct molecular differences from spontaneous osteoarthritis, impacting therapeutic development. This review explores molecular targets for PTOA, focusing on clinical translation challenges.
Area of Science:
- Orthopedics
- Rheumatology
- Molecular Biology
Background:
- Osteoarthritis (OA) is a major cause of disability with significant socioeconomic costs.
- Therapeutic translation for OA has been hindered by discrepancies between preclinical models and human disease.
- Current animal models often mimic post-traumatic OA (PTOA) rather than spontaneous OA.
Purpose of the Study:
- To review molecular targets for PTOA prevention and modification.
- To summarize findings from genetically modified mouse studies.
- To identify challenges in translating PTOA therapies to human clinical trials.
Main Methods:
- Review of studies using genetically modified mice to investigate PTOA pathophysiology.
- Analysis of preclinical therapeutic trial data for PTOA targets.
- Evaluation of translation of findings from animal models to human clinical settings.
Main Results:
- Genetically modified mouse studies reveal distinct molecular pathways in PTOA compared to spontaneous OA.
- Specific molecular targets have shown promise in preclinical PTOA models.
- Differences in disease mechanisms between animal models and human OA contribute to therapeutic translation failures.
Conclusions:
- Understanding PTOA's unique molecular basis is crucial for developing effective disease-modifying therapies.
- Translating preclinical findings for PTOA requires careful consideration of human disease complexity.
- Addressing challenges in clinical trial design is essential for successful PTOA drug development.
